Isomorphic Labs closes $5B funding round for drug discovery AI
SiliconANGLE: Alphabet’s Isomorphic Labs raises $5B to accelerate drug discovery with AI
Isomorphic Labs Ltd. today announced that it has closed a $5 billion investment led by Greenoaks and Sequoia Capital. The venture capital firms were joined by more than a half-dozen other backers. The group included Isomorphic parent Alphabet Inc., which made a “significant investment.” The search giant provided the capital through its GV and CapitalG startup […] The post Alphabet’s Isomorphic Labs raises $5B to accelerate drug discovery with AI appeared first on SiliconANGLE.
Part of a story that several outlets report: Isomorphic Labs raises $5B for AI drug discovery
Isomorphic Labs, a unit of Alphabet, closed a $5 billion investment round led by venture capital firms to develop AI software that speeds up drug discovery. The software platform, called the Drug Design Engine, helps pharmaceutical companies identify where drugs can attach to disease-causing proteins and develop compounds to target those attachment points, skipping steps that normally require expensive hardware and complex laboratory procedures. Multiple pharmaceutical companies are already using the platform for drug discovery programs, and the company plans to use the funding to build new infrastructure and move toward clinical trials.
One short email a day with the stories that matter. Free. Unsubscribe with one click.
Want to go deeper than the news? Explore live, cohort-based AI courses taught by practitioners.
Browse AI courses on Maven
Anthropic reportedly prices IPO at $83 a share, above projected range
The long-awaited IPO reportedly values the company at $1.5 trillion on a fully diluted basis.
Also reported by Crunchbase News, SiliconANGLE, Wired AI and The Verge

Amazon and Google will together own nearly 30% of Anthropic after its IPO
Amazon will own just under 15% of Anthropic after the IPO, with the option to go much higher. Google is a close second with holdings of nearly 14%.
Also reported by Crunchbase News

Anthropic starts trading on Wall Street
Anthropic CEO Dario Amodei speaks at the Nasdaq ahead of his company’s public debut. | Photo by Michael Nagle/Bloomberg via Getty Images Anthropic has officially gone public. It began trading on the Nasdaq under the ticker symbol "ANT" at $111.50 per share, up from its initial $83 per share price that put company's value at around $1.5 trillion. The listing comes nearly a month after Anthropic revealed its plans to go public. In its lengthy S-1 filing, the AI company reported re
Anthropic goes public, but is it too late to save the AI trade?
Anthropic came through with its initial public offering Thursday, but did it just signal a top in the AI trade? The artificial intelligence model maker’s IPO went almost picture-perfectly, really, producing a 17% pop that wasn’t so high that it left an excessive amount of money on the table but high enough to call it […] The post Anthropic goes public, but is it too late to save the AI trade? appeared first on SiliconANGLE.
Medical AI startup Boltz raises $110M to speed up small molecule research
Boltz PBC, a startup that develops artificial intelligence models for pharmaceutical researchers, has raised $110 million in funding. Bessemer led the Series A investment. Boltz stated on Wednesday that the fund was joined by a large group of new and returning backers. The consortium included Greycroft, Andreessen Horowitz, Amplify Partners, F-Prime Capital, Hummingbird and others. […] The post Medical AI startup Boltz raises $110M to speed up small molecule research appeared first on Sili

Anthropic’s compute spending is increasing by 4x per year, outpacing OpenAI’s 3x
Anthropic spent nearly $10 billion on compute and infrastructure in the third quarter of 2026, or close to $40 billion on an annualized basis, up from just $433 million in 2023.